Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 20
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) 32
Nov 11, 2019: Amgen highlights data to be presented on Repatha at AHA 2019 Across Cardiovascular Portfolio 32
Nov 06, 2019: The Medicines company to present inclisiran data from ORION-9 and ORION-10 pivotal phase 3 clinical studies at American Heart Association Scientific Sessions 2019 33
Sep 17, 2019: Arrowhead reports initial data for cardiometabolic candidates 33
Sep 16, 2019: Arrowhead Pharmaceuticals presents initial top-line clinical data and preclinical data on RNAi Candidate ARO-APOC3 34
Clinical Trial Profile Snapshots 35
Appendix 303
Abbreviations 303
Definitions 303
Research Methodology 304
Secondary Research 304
About GlobalData 305
Contact Us 305
Source 306
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2019* 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 15
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 19
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019* 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2019* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 27
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 30
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 31
List of Figures
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 15
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 19
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019* 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 27
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 30
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 31
GlobalData Methodology 304
【免責事項】
https://www.marketreport.jp/reports-disclaimer